Prospective, multicenter, randomized, double-blind, parallel group, placebo-controlled, Phase 3 superiority study with three infusion cycles of study drug, Panzyga, or placebo administered over 2 days every three weeks for a total of nine weeks, with an additional double-blind, crossover safety and effectiveness follow-up phase of three infusion cycles of Panzyga or placebo administered over 2 days every three weeks for a total of nine weeks.
If your child is between the ages of 6 and 17 and has a confirmed diagnosis of moderate to severe Pediatric Acute-onset Neuropsychiatric Syndrome (PANS), then they may be eligible to participate in this study.
Tina Birdsong 501-364-2251 or birdsongtd@archildrens.org
Español 
Cookie Settings 
Accessibility